Calidi Biotherapeutics Debuts as a Publicly Traded Company Focused on Arming the Immune System to Fi

Business combination transaction with First Light Acquisition Group, a special purpose acquisition company, completed on September 12, 2023Gross proceeds made available to Calidi Biotherapeutics from transaction total approximately $28 million, including funds held in First Light Acquisition Group’s trust account be...

Related Keywords

California ,United States ,Lincoln Park ,San Diego ,Ukraine ,American ,Tom Vecchiolla ,Allan Camaisa ,Calidi Biotherapeutics ,First Light Acquisition Group ,Division Of Arcadia Securities ,Gotshal Manges ,Lewis Brisbois Bisgaard Smith ,Exchange Commission ,New York Stock Exchange ,York Stock Exchange American ,Great Point Capital ,York Stock Exchange ,California Institute For Regenerative Medicine ,First Light Acquisition Group Inc ,Meteora Capital ,Calidi Biotherapeutics Inc ,Lincoln Park Capital Fund ,Funicular Funds ,New York Stock Exchange American ,Chief Executive Officer ,Chairman Allan Camaisa ,First Light Acquisition ,Lancet Oncology ,Translational Medicine ,California Institute ,Regenerative Medicine ,Investigational New Drug ,Capital Markets ,Arcadia Securities ,Calidi Seriesb Preferred Stock Financing ,Lewis Brisbois Bisgaard ,Business Combination ,Note Regarding Forward Looking ,